Evidence map›Paper›PMID 41458719›Full record

ArticleCureus2025

Challenges in Meeting Dose Constraints During Left Postmastectomy Radiotherapy in a Patient With a Leadless Pacemaker.

Koyo Kikuchi, Ibuki Ota, Hiromori Sasaki, Ryuji Nakamura

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Koyo KikuchiRadiation Oncology, Iwate Medical University, Yahaba-cho, JPN.
Ibuki OtaRadiation Oncology, Iwate Prefectural Central Hospital, Morioka, JPN.
Hiromori SasakiRadiation Oncology, Iwate Prefectural Central Hospital, Morioka, JPN.
Ryuji NakamuraRadiology, Morioka Red Cross Hospital, Morioka, JPN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 60-year-old woman with a 20-year history of cardiac pacing presented with node-positive left breast cancer and underwent total mastectomy. Postmastectomy radiotherapy (PMRT) was indicated; however, because a subcutaneous pacemaker was located in the left anterior chest wall, it was replaced with a leadless pacemaker (LPM) to avoid direct irradiation. PMRT was planned using three-dimensional conformal radiotherapy with a conventional regimen of 50 Gy in 25 fractions, targeting the left chest wall, supraclavicular region, and internal mammary nodes, followed by a boost of 10 Gy in five fractions to the enlarged left supraclavicular and internal mammary nodes. Based on published guidelines and the manufacturer's specifications, our institutional dose constraints were defined as the maximum point dose <200 cGy for the LPM and <500 cGy for the planning risk volume of the LPM (PRV_LPM; LPM plus a 1-cm margin). The initial calculation revealed doses of 314 cGy to the LPM and 565 cGy to the PRV_LPM, exceeding the limits. To reduce the dose to the LPM, the inferior border of the chest wall field was reduced while maintaining coverage of the surgical scar and enlarged left internal mammary nodes. Consequently, the LPM and PRV_LPM doses decreased to 102 cGy and 154 cGy, respectively, achieving compliance with the predefined constraints. This case demonstrates that LPM implantation alone does not necessarily ensure compliance with device dose limits during conventionally fractionated left-sided PMRT.

Indexed as

breast neoplasmscardiac implantable electronic devicescardiac pacingdose constraintsleadless pacemakermastectomypostmastectomy radiotherapyradiotherapy complicationsradiotherapy planning

Identifiers

PMID41458719
PMCPMC12743192

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.